Product Description: Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2+ breast cancer, gliomas, et al[1].
Applications: Cancer-Kinase/protease
Formula: C21H28N4O5
References: [1]Lois Witters, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008 Sep 1;68(17):7083-9./[2]Fei Yuan, et al. ADAM17 is an essential attachment factor for classical swine fever virus. PLoS Pathog. 2021 Mar 8;17(3):e1009393.
CAS Number: 791828-58-5
Molecular Weight: 416.47
Compound Purity: 99.44
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: MMP
Deutsch
English
